Expert insights. Personalized for you.
Just a few days ago, Pfizer and Biotech announced they are making headway on a vaccine that could be released by spring. As business leaders, we’re always on the lookout for success insights. MORE
We mapped out 1,382 biotechs based in Europe and some interesting themes emerged. Insights on Pharmaceuticals & Medical Products Biotechnology MORE
Even in tough times, investor expectations and deal making in biotech are surging. Can the sector maintain its strong growth? Insights on Pharmaceuticals & Medical Products Venture capital Biotechnology MORE
How a biotech scientist helped transform a traditional science organization into an innovation leader. Strategy & Corporate Finance Insights MORE
Watch the webinar as the assembled team of experts discuss cut through common misconceptions and highlight findings from case studies featuring three different organizations integrating AI from three different sectors (Steel, Retail Banking, and Biotech). What are the real-world impacts of AI on labor and the economy? MORE
The company works with customers across business verticals such as generics and novel drugs, driven mainly by large pharma, specialty pharma, and biotech startups. MORE
As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies.” MORE
Knowledge and understanding of what drives value for biotech, platform and product companies in health as well as knowledge of the specialist investors, banks, analysts. Seeking an individual that wants to join a growing team of health and science communications experts to drive investor targeting and outreach as well as handling of investor meetings with senior management at client companies. Track investor outreach, report and guide on next steps based on feedback. MORE
Wainwright has announced their “Bioconnect” event will be held virtually during the same week as JPM, and the Biotech Showcase, traditionally held at the Hilton in San Francisco, is piloting a new virtual format with advance access for participants beginning as early as this November. MORE
The expanded portfolio will help build long-term relationships with small and mid-sized pharma and biotech sponsors due to increased engagement early on in the drug development process. MORE
Our guest today is COO Alliance Member, Dana Berg the COO of SADA Systems. . As Chief Operating Officer, Dana Berg is driven by the singular mission of identifying and implementing innovative solutions that create competitive advantages for our customers. MORE
World-class science and innovation need to be matched with stronger scale-up capabilities and a broader funding base if Europe is to emerge as a leader in biotech. MORE
Donna discusses what makes strategic communications and investor relations in biotech different from other industries. The communications function is often reliant on the entire strategic leadership team in a startup biotech. MORE
By placing philosophers and artists in key research sites to foster dialogue with technologists, the aim of the program is to render AI and Biotech visible as unusually potent experimental sites for reformulating our vocabulary for thinking about ourselves. Central to our ability to produce unique research is the diversity of our “community of practice.” MORE
An emerging model for biotech companies could disrupt the R&D landscape and open up new ways to invest, motivate teams, and shape the innovation pipeline. MORE
This is what we most often see in pharma and biotech alliances. Last week I was asked a question about where would be the best location for an alliance & partnerships team in an organisation for reporting purposes. MORE
As investments into sustainable companies and funds have surged to new highs, how can biotech and life science companies best position themselves with this burgeoning group of investors. Interviews with our senior practice managers about issues of important to life science innovators. MORE
Elliott noted that there was a global opportunity now for potential acquisitions in biotech and pharmaceuticals, given the high hopes and intense demands created by the pandemic. And is your company prepared for what may be coming next? MORE
LaVoieHealthScience interns work with an innovative account team on key pharma and biotech accounts as well as assisting with agency marketing efforts. Our interns grow professionally through exposure to a wide range of corporate marketing and communications, media relations and investor relations accounts and projects. MORE
The ideal experience is in Biotech, Pharma, Device, MedTech, Public Health & Wellness and will contribute to agency revenue growth by retaining and organically growing the existing portfolio of clients, as well as leveraging his/her relationships and deep experience as a healthcare industry leader, to attract new clients through relationship cultivation and network development. MORE
Based on its recent analysis of the North American market for industrial enterprise performance management, Frost & Sullivan recognizes Pharmactive Biotech Products, S.L. About Pharmactive Biotech Products, S.L. Pharmactive Biotech Products, S.L., MORE
It might make sense for a biotech company, for example, that is researching a new drug and needs ready access to capital. By Russell Tolander. Managing Director. Nano-capitalization public companies, those with a valuation of less than $50 million, have fewer active buyers interested in them in today’s public markets, due to existing trends such as investors’ favoritism toward large companies, technology startups and disruptive or innovative business models (think Uber, Lyft, Amazon). MORE
At the same time, the biotech and pharmaceutical industries are in the spotlight as never before as nations and companies push programs to try to develop vaccines and therapeutics for the virus faster than drugs have ever been created before. MORE
Biotech Related Topics McKinsey & Company
JUNE 29, 2021
World-class science and innovation need to be matched with stronger scale-up capabilities and a broader funding base if Europe is to emerge as a leader in biotech.
McKinsey & Company
JANUARY 29, 2021
An emerging model for biotech companies could disrupt the R&D landscape and open up new ways to invest, motivate teams, and shape the innovation pipeline.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Frost & Sullivan
JULY 22, 2021
As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies.”
McKinsey & Company
APRIL 30, 2021
Even in tough times, investor expectations and deal making in biotech are surging. Can the sector maintain its strong growth? Insights on Pharmaceuticals & Medical Products Venture capital Biotechnology
McKinsey & Company
JULY 29, 2021
We mapped out 1,382 biotechs based in Europe and some interesting themes emerged. Insights on Pharmaceuticals & Medical Products Biotechnology
McKinsey & Company
FEBRUARY 9, 2021
How a biotech scientist helped transform a traditional science organization into an innovation leader. Strategy & Corporate Finance Insights
Peter Simoons
FEBRUARY 28, 2021
This is what we most often see in pharma and biotech alliances. Last week I was asked a question about where would be the best location for an alliance & partnerships team in an organisation for reporting purposes.
LaVoie Health Science Blog
OCTOBER 5, 2020
Knowledge and understanding of what drives value for biotech, platform and product companies in health as well as knowledge of the specialist investors, banks, analysts. Seeking an individual that wants to join a growing team of health and science communications experts to drive investor targeting and outreach as well as handling of investor meetings with senior management at client companies. Track investor outreach, report and guide on next steps based on feedback.
LaVoie Health Science Blog
JULY 16, 2021
As investments into sustainable companies and funds have surged to new highs, how can biotech and life science companies best position themselves with this burgeoning group of investors. Interviews with our senior practice managers about issues of important to life science innovators.
LaVoie Health Science Blog
SEPTEMBER 3, 2020
At the same time, the biotech and pharmaceutical industries are in the spotlight as never before as nations and companies push programs to try to develop vaccines and therapeutics for the virus faster than drugs have ever been created before.
LaVoie Health Science Blog
AUGUST 3, 2020
LaVoieHealthScience interns work with an innovative account team on key pharma and biotech accounts as well as assisting with agency marketing efforts. Our interns grow professionally through exposure to a wide range of corporate marketing and communications, media relations and investor relations accounts and projects.
LaVoie Health Science Blog
JANUARY 11, 2021
The ideal experience is in Biotech, Pharma, Device, MedTech, Public Health & Wellness and will contribute to agency revenue growth by retaining and organically growing the existing portfolio of clients, as well as leveraging his/her relationships and deep experience as a healthcare industry leader, to attract new clients through relationship cultivation and network development.
LaVoie Health Science Blog
OCTOBER 14, 2020
Wainwright has announced their “Bioconnect” event will be held virtually during the same week as JPM, and the Biotech Showcase, traditionally held at the Hilton in San Francisco, is piloting a new virtual format with advance access for participants beginning as early as this November.
Frost & Sullivan
MARCH 23, 2021
Based on its recent analysis of the North American market for industrial enterprise performance management, Frost & Sullivan recognizes Pharmactive Biotech Products, S.L. About Pharmactive Biotech Products, S.L. Pharmactive Biotech Products, S.L.,
CoSell Blog
JANUARY 14, 2021
Just a few days ago, Pfizer and Biotech announced they are making headway on a vaccine that could be released by spring. As business leaders, we’re always on the lookout for success insights.
COO Alliance
MAY 30, 2021
Our guest today is COO Alliance Member, Dana Berg the COO of SADA Systems. . As Chief Operating Officer, Dana Berg is driven by the singular mission of identifying and implementing innovative solutions that create competitive advantages for our customers.
Frost & Sullivan
APRIL 21, 2021
The expanded portfolio will help build long-term relationships with small and mid-sized pharma and biotech sponsors due to increased engagement early on in the drug development process.
Partnership on AI
AUGUST 2, 2019
Watch the webinar as the assembled team of experts discuss cut through common misconceptions and highlight findings from case studies featuring three different organizations integrating AI from three different sectors (Steel, Retail Banking, and Biotech). What are the real-world impacts of AI on labor and the economy?
LaVoie Health Science Blog
JULY 1, 2020
Elliott noted that there was a global opportunity now for potential acquisitions in biotech and pharmaceuticals, given the high hopes and intense demands created by the pandemic. And is your company prepared for what may be coming next?
Frost & Sullivan
MARCH 8, 2021
The company works with customers across business verticals such as generics and novel drugs, driven mainly by large pharma, specialty pharma, and biotech startups.
The Capital Alliance Blog
MARCH 9, 2020
It might make sense for a biotech company, for example, that is researching a new drug and needs ready access to capital. By Russell Tolander. Managing Director. Nano-capitalization public companies, those with a valuation of less than $50 million, have fewer active buyers interested in them in today’s public markets, due to existing trends such as investors’ favoritism toward large companies, technology startups and disruptive or innovative business models (think Uber, Lyft, Amazon).
Partnership on AI
MAY 15, 2019
By placing philosophers and artists in key research sites to foster dialogue with technologists, the aim of the program is to render AI and Biotech visible as unusually potent experimental sites for reformulating our vocabulary for thinking about ourselves. Central to our ability to produce unique research is the diversity of our “community of practice.”
158 
Let's personalize your content